MADRIGAL PHARMACEUTICALS, INC.
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
MDGL | US
Overview
Corporate Details
- ISIN(s):
- US5588681057
- LEI:
- Country:
- United States of America
- Address:
- 200 BARR HARBOR DRIVE, SUITE 400, 19428 WEST CONSHOHOCKEN
- Website:
- https://www.madrigalpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Madrigal Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. The company's research led to the development of the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for MASH. Madrigal's primary therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease, thereby preventing progression to severe complications such as cirrhosis, liver failure, and the need for transplantation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all MADRIGAL PHARMACEUTICALS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MADRIGAL PHARMACEUTICALS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MADRIGAL PHARMACEUTICALS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Ltd/other/HUTCHMED_China_Ltd-logo.png){kind=logo}
